Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


Giant malignant phyllodes tumor with metastasis to the brain.

Gregston AP, Metter DM, Osborne CRC, Pippen J Jr.

Proc (Bayl Univ Med Cent). 2019 Jan 15;32(1):116-118. doi: 10.1080/08998280.2018.1521207. eCollection 2019 Jan.


Can synthetic urine replace authentic urine to "beat" workplace drug testing?

Kim VJ, Okano CK, Osborne CR, Frank DM, Meana CT, Castaneto MS.

Drug Test Anal. 2019 Feb;11(2):331-335. doi: 10.1002/dta.2497. Epub 2018 Oct 14.


Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.

Holmes FA, Hellerstedt BA, Pippen JE Jr, Vukelja SJ, Collea RP, Kocs DM, Blum JL, McIntyre KJ, Barve MA, Brooks BD, Osborne CR, Wang Y, Asmar L, O'Shaughnessy J.

Cancer Med. 2018 Jun;7(6):2288-2298. doi: 10.1002/cam4.1472. Epub 2018 Mar 26.


Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.

Holmes FA, Espina V, Liotta LA, Nagarwala YM, Danso M, McIntyre KJ, Osborne CR, Anderson T, Krekow L, Blum JL, Pippen J, Florance A, Mahoney J, O'Shaughnessy JA.

BMC Res Notes. 2013 Dec 5;6:507. doi: 10.1186/1756-0500-6-507.


Our experience as a Health Volunteers Overseas-sponsored team in Huê´, Vietnam.

Ewing JI, Denham CA, Osborne CR, Green NB, Divers J, Pippen JE Jr.

Proc (Bayl Univ Med Cent). 2013 Apr;26(2):137-41.


Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.

Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, Aitelli CL, Osborne CR, Izatt T, Kurdoglu A, Baker A, Koeman J, Barbacioru C, Sakarya O, De La Vega FM, Siddiqui A, Hoang L, Billings PR, Salhia B, Tolcher AW, Trent JM, Mousses S, Von Hoff D, Carpten JD.

Mol Cancer Ther. 2013 Jan;12(1):104-16. doi: 10.1158/1535-7163.MCT-12-0781. Epub 2012 Nov 19.


The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.

Osborne CR, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, Kasper M, Wilks S, Schneider A, McGee R, Meyer WG, O'Shaughnessy JA.

Breast Cancer Res Treat. 2009 Aug;116(3):521-7. doi: 10.1007/s10549-008-0284-y. Epub 2009 Jan 13.


Supplemental Content

Loading ...
Support Center